- Home
- SDRL vs DAWN Comparison
SDRL vs DAWN Comparison
Compare SDRL & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDRL | DAWN |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.2B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SDRL | DAWN |
|---|---|---|
| Price | $46.10 | $21.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $56.00 | $24.43 |
| AVG Volume (30 Days) | 633.6K | ★ 1.7M |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.61 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,437,000,000.00 | $158,182,000.00 |
| Revenue This Year | $5.22 | $55.03 |
| Revenue Next Year | $14.20 | $28.12 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 3.75 | ★ 20.60 |
| 52 Week Low | $19.60 | $5.64 |
| 52 Week High | $48.99 | $21.50 |
Technical Indicators
Market Signals| Indicator | SDRL | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 52.64 | 79.77 |
| Support Level | $41.63 | $10.30 |
| Resistance Level | $48.99 | $21.50 |
| Average True Range (ATR) | 1.79 | 0.03 |
| MACD | -0.18 | -0.32 |
| Stochastic Oscillator | 38.65 | 77.27 |
Price Performance
Historical ComparisonAbout SDRL Seadrill Limited
Seadrill Ltd is an offshore drilling contractor company. The company is engaged in providing offshore drilling services to the oil and gas industry. The primary business of the company is the ownership and operation of drillships, semi-submersible rigs, and jack-up rigs for operations in shallow to ultra-deepwater areas in both benign and harsh environments. The geographical segments of the company are the United States, Brazil, Angola, Norway, Canada and others. The company derives maximum revenue from the United States.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.